Edwards Lifesciences Corporation $EW Shares Acquired by Mission Wealth Management LP

Mission Wealth Management LP boosted its position in Edwards Lifesciences Corporation (NYSE:EW) by 2.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 45,530 shares of the medical research company’s stock after buying an additional 1,073 shares during the quarter. Mission Wealth Management LP’s holdings in Edwards Lifesciences were worth $3,561,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in EW. Quantbot Technologies LP acquired a new stake in shares of Edwards Lifesciences during the first quarter worth $26,000. SouthState Corp bought a new position in Edwards Lifesciences in the first quarter worth about $27,000. Rosenberg Matthew Hamilton bought a new position in shares of Edwards Lifesciences during the second quarter valued at approximately $28,000. Rossby Financial LCC bought a new stake in shares of Edwards Lifesciences in the 1st quarter worth approximately $29,000. Finally, Costello Asset Management INC acquired a new position in Edwards Lifesciences during the 1st quarter valued at approximately $29,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

EW has been the topic of several analyst reports. Daiwa America raised Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 29th. Mizuho upped their price target on shares of Edwards Lifesciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research report on Friday. Stifel Nicolaus increased their price objective on shares of Edwards Lifesciences from $85.00 to $95.00 and gave the stock a “buy” rating in a report on Friday. Robert W. Baird set a $83.00 target price on shares of Edwards Lifesciences in a research note on Friday. Finally, BTIG Research upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 target price for the company in a research report on Tuesday, July 29th. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $91.00.

Edwards Lifesciences Price Performance

NYSE EW opened at $82.48 on Monday. Edwards Lifesciences Corporation has a 1 year low of $64.89 and a 1 year high of $87.09. The business’s fifty day moving average is $77.58 and its two-hundred day moving average is $76.97. The stock has a market capitalization of $48.42 billion, a P/E ratio of 11.87, a P/E/G ratio of 3.97 and a beta of 1.05. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. The business had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company’s quarterly revenue was up 14.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. On average, research analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the business’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the sale, the insider owned 206,900 shares in the company, valued at approximately $16,150,614. The trade was a 4.15% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.